Previous research suggested that gram-negative bacteria may hold potential for cancer immunotherapy because they contain agonists for multiple immune receptors.
Cancervax Inc. has selected pancreatic ductal adenocarcinoma (PDAC) as one of its first targets for preclinical development using its novel universal cancer treatment (UCT) platform.
Polypid Ltd. has entered into a new research and development collaboration with Immunogenesis Inc. for the development of novel formulations utilizing Polypid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology and Immunogenesis’ potent STING agonist drug candidate to potentially enhance treatment for solid tumors.
In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell therapy being developed for the treatment of B-cell malignancies.
Nextcure Inc. has reported IND clearance from the FDA enabling initiation of a phase I trial of LNCB-74, a B7-H4-targeting antibody-drug conjugate (ADC) being developed for various cancers.
With the aim of developing an effective and more tolerable conditioning for hematopoietic stem cell transplantation (HSCT), researchers from Molecular Partners AG applied the proprietary ankyrin repeat protein (DARPin) platform to generate a novel multi-specific Switch-DARPin candidate, MP-0621.
Researchers from the Children's Hospital of Philadelphia presented data from a study that aimed to identify novel biologically relevant cell surface immunotherapeutic targets for neuroblastoma.
Medigene AG has announced the selection of KRAS G12V, in the context of HLA*A11, as the initial target for the co-development of T-cell receptor-guided T-cell engagers (TCR-TCEs) with Wuxi Biologics Co. Ltd.
RSS
